Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 188

The DOI matches its Crossref record.

Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study

Open access
Mayer, Lloyd, Sandborn, William J, Stepanov, Yuriy, Geboes, Karel, Hardi, Robert, Yellin, Michael, Tao, Xiaolu, Xu, Li An, Salter-Cid, Luisa, Gujrathi, Sheila, Aranda, Richard, Luo, Allison Y·2014·Gut

Abstract

Objective: Interferon-γ-inducible protein-10 (IP-10 or CXCL10) plays a role in inflammatory cell migration and epithelial cell survival and migration. It is expressed in higher levels in the colonic tissue and plasma of patients with ulcerative colitis (UC). This phase II study assessed the efficacy and safety of BMS-936557, a fully human, monoclonal antibody to IP-10, in the treatment of moderately-to-severely active UC. Design: In this 8-week, phase II, double-blind, multicentre, randomised study, patients with active UC received placebo or BMS-936557 (10 mg/kg) intravenously every other week. The primary endpoint was the rate of clinical response at Day 57; clinical remission and mucosal healing rates were secondary endpoints. Post hoc analyses evaluated the drug exposure–response relationship and histological improvement. Results: 109 patients were included (BMS-936557: n=55; placebo: n=54). Prespecified primary and secondary endpoints were not met; clinical response rate at Day 57 was 52.7% versus 35.2% for BMS-936557 versus placebo (p=0.083), and clinical remission and mucosal healing rates were 18.2% versus 16.7% (p=1.00) and 41.8% versus 35.2% (p=0.556), respectively. However, higher BMS-936557 steady-state trough concentration (C minss ) was associated with increased clinical response (87.5% vs 37.0% (p<0.001) for patients with C minss 108–235 μg/ml vs placebo) and histological improvements (73.0% vs 41.0%; p=0.004). Infections occurred in 7 (12.7%) BMS-936557-treated patients and 3 (5.8%) placebo-treated patients. 2 (3.6%) BMS-936557 patients discontinued due to adverse events. Conclusions: Anti-IP-10 antibody, BMS-936557, is a potentially effective therapy for moderately-to-severely active UC. Higher drug exposure correlated with increasing clinical response and histological improvement. Further dose–response studies are warranted. Clinical Trial Registration Number: ClinicalTrials.gov NCT00656890 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2012-303424

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 188

Metadata

Authors
Mayer, L., Sandborn, W. J., Stepanov, Y., Geboes, K., Hardi, R., Yellin, M., Tao, X., Xu, L. A., Salter-Cid, L., Gujrathi, S., Aranda, R., & Luo, A. Y.
Venue
Gut
Publisher
BMJ
Published
2013-03-05
Volume
63
Issue
3
Pages
442-450
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2169559894
Cited by
188
References
0
FWCI
9.31
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. https://app.cochat.ai/papers/10.1136/gutjnl-2012-303424
The paper
Mayer, L., Sandborn, W. J., Stepanov, Y., Geboes, K., Hardi, R., Yellin, M., Tao, X., Xu, L. A., Salter-Cid, L., Gujrathi, S., Aranda, R., & Luo, A. Y. (2014). Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. https://doi.org/10.1136/gutjnl-2012-303424

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.